Vanguard Group
KYTX icon

Vanguard Group’s Kyverna Therapeutics KYTX Stock Holding History

Vanguard Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$16.7M Buy
1,781,257
+458,632
+35% +$3.4M ﹤0.01% 2705
2025
Q3 		$7.94M Buy
1,322,625
+9,858
+0.8% +$39.4K ﹤0.01% 3101
2025
Q2 		$4.03M Buy
1,312,767
+14,318
+1% +$35.4K ﹤0.01% 3288
2025
Q1 		$2.51M Sell
1,298,449
-14,783
-1% -$43.7K ﹤0.01% 3419
2024
Q4 		$4.91M Buy
1,313,232
+306,525
+30% +$1.47M ﹤0.01% 3279
2024
Q3 		$4.92M Sell
1,006,707
-9,914
-1% -$76.4K ﹤0.01% 3278
2024
Q2 		$7.62M Buy
1,016,621
+752,406
+285% +$11.5M ﹤0.01% 3061
2024
Q1 		$6.56M Buy
+264,215
New +$7.37M ﹤0.01% 3182

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group's KYTX Position: Q4 2025 in Review

Vanguard Group increased its Kyverna Therapeutics (KYTX) stake by 35% in Q4 2025, buying an estimated $3.4M and bringing the position to 1,781,257 shares worth $16.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2705.

Vanguard Group first reported a position in KYTX in Q1 2024 and has held it in 8 quarters since. 99 funds tracked by Wall St. Rank hold KYTX as of Q4 2025.

  • Vanguard Group held 1,781,257 shares of Kyverna Therapeutics worth $16.7M as of Q4 2025.
  • Vanguard Group bought 458,632 Kyverna Therapeutics shares in Q4 2025, an estimated $3.4M.
  • Kyverna Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2705 holding.
  • Vanguard Group first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • 99 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.